Meta-analysis of Pitavastatin in the treatment of hyperlipemia mixed with type 2 diabetes mellitus
PAN Dan1 CHEN Kuixia1 LI Li1 SU Weiwei2 WANG Qian1 LU Shan1 YUAN Ying3 ZHAO Kexin1
1.Department of Pharmacy, Hebei Petro China Central Hospital, Hebei Province, Langfang 065000, China;
2.Department of Neurology, Hebei Petro China Central Hospital, Hebei Province, Langfang 065000, China;
3.Department of Respiratory Medicine, the Third People′s Hospital of Langfang, Hebei Province, Langfang 065000, China
Abstract：Objective To systematically evaluate the effect and safety of Pitavastatin in the treatment of hyperlipemia mixed with type 2 diabetes mellitus. Methods CNKI database, VIP database, Wanfang database, Cochoran Library, EMbase database and PubMed database were searched, and the search time was from November 1999 to June 2018. Randomized controlled tirals comparing Pitvastatin with Atorvastatin in the treatment of hyperlipemia mixed with type 2 diabetes mellitus were collected. The literatures were read and the information was extracted independently by two reviewers, a third party was requested to assist in case of disagreement. RevMan 5.0 statistical software was used to conduct a meta-analysis on the changes of fasting plasma glucose, glycosylated hemoglobin, total cholesterol and low density lipoprotein cholesterol and the occurrence of adverse reactions in the two groups. Results A total of 13 studies involving 1472 patients were included. Fasting plasma glucose levels of the test group were lower than those of the control group, with statistically significant differences (MD = -0.81, 95%CI: -1.20, -0.41, P < 0.0001). Glycosylated hemoglobin levels of the test group were lower than those of the control group, with statistically significant differences (MD = -0.37, 95%CI:-0.53, -0.21, P ＜ 0.000 01). There was no significant difference in total cholesterol levels between the two groups （MD = -0.01，95%CI:-0.06, 0.04，P > 0.05）. There was no significant difference in low density lipoprotein cholesterol levels between the two groups（MD = -0.00，95%CI:-0.06, 0.06，P > 0.05）. There was no significant difference in the incidence of adverse reaction between two groups(OR = 0.48, 95%CI:0.19, 1.20，P > 0.05). Conclution Pitavastatin is better Atorvastatin of lowering blood glucose in patients with dyslipidemia and diabetes inellitus, and the safety of the two drugs is similar.
潘丹1 陈魁霞1 李立1 苏微微2 王倩1 卢姗1 袁影3 赵可新1. 匹伐他汀治疗血脂异常合并糖尿病患者的meta分析[J]. 中国医药导报, 2020, 17(6): 127-130,135.
PAN Dan1 CHEN Kuixia1 LI Li1 SU Weiwei2 WANG Qian1 LU Shan1 YUAN Ying3 ZHAO Kexin1. Meta-analysis of Pitavastatin in the treatment of hyperlipemia mixed with type 2 diabetes mellitus. 中国医药导报, 2020, 17(6): 127-130,135.
[1] 廖玉华，程翔，黄恺，等.ASCVD患者逆转斑块他汀治疗专家共识[J].临床心血管病杂志，2015，31（1）：1-5.
[2] 温金华，熊玉卿.匹伐他汀的药代动力学特征[J].中国临床药理学杂志，2008，24（4）：364-367.
[3] Zaharan NL，Williams D，Bennett K. Statins and risk of treated incident diabetes in a primary care population [J]. Br J Clin Pharmacol，2013，75（4）：1118-1124.
[4] Yasuyuki Y，Sato-Ishida R，Motoyama A. Place of pitavastatin in the statin armamentarium promising evidence for a role in diabetes mellitus [J]. Drug Des Dev Ther，2011，5：283-297.
[5] 毛勇，余金明，张芬,等.匹伐他汀对血糖的效应及其治疗糖尿病高胆固醇血症的疗效[J].中华内科杂志，2012， 51（7）：508-512.
[6] 中华医学会糖尿病学分会.中国2型糖尿病防治指南（2017年版）[J].中国糖尿病杂志，2018，10（1）：4-67.
[7] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南：2016年修订版[J].中国循环杂志，2016，31（10）：937-953.
[8] Jadad AR，Mood RA，Carroll D，et al. Assessing the quality of reports of randomized clinical trials：is blinding necessary？[J]. Control Clin Trials，1996，17（1）：1-12.
[9] Shimabukuro M，Higa M，Tanaka H，et al. Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus [J]. Diabet Med，2011，28：856-864.
[10] Liu PY，Lin LY，Lin HJ，et al. Pitavastatin and atorvastatin double-blind randomized comparative study among high-risk patients，including those with type 2 diabetes mellitus，in Taiwan（PAPAGO-T study）[J]. PLoS One，2013，8（10）：e76298.
[11] Mita T，Nakayama S，Abe H，et al. Comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia [J]. J Diabetes Investig，2013，4（3）：297-303.
[12] Yamakawa T，Takano T，Tanka S，et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus [J]. J Atheroscler Thromb，2008，15（5）：269-275.
[13] Yokote K，Saito Y，CHIBA. Influence of Statins on Glucose Tolerance in Patients with Type 2 Diabetes Mellitus：Subanalysis of the Collaborative Study on Hypercholesterolemia Drug Intervention and their Benefits for Atherosclerosis Prevention （CHIBA Study） [J]. J Ather-oscler Thromb，2009，16（3）：297-298.
[14] 李鸣.匹伐他汀对血糖的效应及其治疗糖尿病高胆固醇血症的临床疗效[J].临床研究，2016，24（1）：74-75.
[15] 肖艳，邵蔚，刘宇，等.匹伐他汀治疗糖尿病合并高胆固醇血症的临床观察[J].中华肿瘤防治杂志，2016，23（S1）：253-254.
[16] 吴能森，练汉健，杜小安.匹伐他汀治疗2型糖尿病合并高胆固醇血症临床疗效[J].中国现代药物应用，2018， 12（9）：119-120.
[17] 严兆丹，肖金华，张令晖，等.匹伐他汀的降糖效果及其治疗糖尿病高胆固醇血症的疗效[J].临床和实验医学杂志，2014，13（10）：813-816.
[18] 李洋.匹伐他汀治疗糖尿病合并高胆固醇血症的临床效果观察[J].中国医药指南，2016，14（5）：126-127.
[19] 杜小宇，傅强，汪娟，等.匹伐他汀治疗糖尿病高胆固醇血症的疗效研究[J].检验医学与临床，2015，12（4）：513-514.
[20] 景海燕.匹伐他汀治疗糖尿病高胆固醇血症的疗效观察[J].中国实用医药，2016，11（9）：154-155.
[21] 岳晨，刘小利.匹伐他汀对血糖的效应及其治疗糖尿病高胆固醇血症的临床疗效[J].糖尿病新世界，2016：43-44.
2020, Vol. 17 
京公网安备 11010502046598号